Venezuela Clinical Trial Timeline: From Protocol to Patient Enrollment in 18-33 Weeks
A detailed phase-by-phase breakdown of the Venezuela clinical trial timeline — from initial CRO engagement through INHRR regulatory submission to first patient enrollment.
May 8, 2026
13
min read
By
bioaccess® Editorial Team
Venezuela clinical trial timeline
clinical trial enrollment Venezuela
INHRR approval timeline
Latin America clinical research
clinical trial phases Venezuela
**Key Takeaways**
- • Total timeline: 18-33 weeks from CRO engagement to first patient enrolled
- • 6 distinct phases: CRO engagement → site selection → regulatory → ethics → activation → enrollment
- • INHRR review: 8-16 weeks for scientific and administrative evaluation
- • Parallel processing: Ethics and regulatory submissions can partially overlap
- • Cost advantage: 40-60% operational savings vs. US/EU markets
Timeline overview: clinical trial startup in Venezuela
Launching a clinical trial in Venezuela involves a structured sequence of regulatory, ethical, and operational steps. For international sponsors evaluating Venezuela as a first-in-human clinical trial destination, understanding the realistic timeline is critical for program planning and investor communications.
The total timeline from initial CRO engagement to first patient enrolled ranges from 18 to 33 weeks, depending on protocol complexity, document readiness, and investigational product logistics. bioaccess®, as the first CRO to establish clinical trial operations in Venezuela, has optimized each phase to minimize delays.
Phase 1: CRO engagement and regulatory strategy (Weeks 1-4)
The first phase involves selecting and engaging an experienced local CRO — a decision that has an outsized impact on the overall timeline. During this phase, bioaccess® conducts a comprehensive feasibility assessment and develops a regulatory strategy tailored to the sponsor's protocol and development objectives.
- Protocol feasibility review and regulatory pathway analysis
- Budget development and contract negotiation
- Regulatory strategy for INHRR submission
- Preliminary site identification based on therapeutic area
- Investigational product import logistics planning
Phase 2: Site selection and investigator identification (Weeks 3-8)
Venezuela offers a growing network of 60,000+ trained physicians and well-equipped private hospital infrastructure. bioaccess® leverages its established investigator relationships to identify qualified principal investigators with relevant therapeutic expertise and GCP training.
- Site capability assessments across Caracas, Valencia, Maracaibo, and Barquisimeto
- Principal investigator qualification review and GCP verification
- Site infrastructure evaluation (lab, pharmacy, imaging capabilities)
- Patient population assessment for enrollment feasibility
- Sub-investigator and study coordinator identification
Phase 3: Regulatory submission to INHRR (Weeks 6-22)
The INHRR submission and review phase is the longest single component of the timeline. A complete Clinical Trial Application (CTA) is submitted to INHRR for scientific and administrative review, with the review period typically lasting 8-16 weeks.
| Activity | Duration | Notes |
|---|---|---|
| CTA document preparation & translation | 4-6 weeks | All documents must be in Spanish |
| INHRR submission | 1 week | Complete package with ethics approval |
| INHRR scientific review | 8-16 weeks | May include queries |
| Query responses | 2-4 weeks | If requested by INHRR |
| Authorization issuance | 1-2 weeks | Final approval letter |
Phase 4: Ethics committee review (Weeks 4-12)
Ethics committee review in Venezuela runs partially in parallel with the INHRR submission process. The institutional ethics committee at the selected clinical trial site must approve the protocol before INHRR can issue its final authorization.
- Submission to institutional Comité de Ética de la Investigación
- Protocol and ICF review (4-8 weeks)
- Risk-benefit assessment and participant protection review
- Insurance/indemnity documentation verification
- Approval letter issuance for inclusion in INHRR package
Phase 5: Site activation and IP import (Weeks 18-29)
Once INHRR authorization and ethics approval are secured, site activation begins. This phase includes investigational product import — a step that requires advance planning due to customs and import authorization requirements.
- INHRR import authorization for investigational products
- Customs clearance and cold chain logistics coordination
- Site initiation visit (SIV) and staff training
- IRB/IEC-approved ICF finalization and printing
- EDC system setup and data management infrastructure
- Randomization and drug accountability procedures
Phase 6: First patient enrollment (Weeks 20-33)
With site activation complete and investigational product on-site, patient screening and enrollment can begin. Venezuela's treatment-naïve patient populations and high disease prevalence rates can enable faster enrollment than traditional markets.
**Enrollment advantage**
Venezuela's treatment-naïve populations mean patients often have not been exposed to standard-of-care therapies available in the US or Europe, making them ideal candidates for first-in-human and proof-of-concept studies. This can accelerate enrollment timelines by 30-50% compared to US sites.
Gantt-style timeline breakdown
The following table shows how the 6 phases overlap and flow sequentially:
| Phase | Start Week | End Week | Duration |
|---|---|---|---|
| 1. CRO engagement & strategy | Week 1 | Week 4 | 4 weeks |
| 2. Site selection & investigators | Week 3 | Week 8 | 6 weeks |
| 3. Regulatory (INHRR) submission | Week 6 | Week 22 | 16 weeks |
| 4. Ethics committee review | Week 4 | Week 12 | 8 weeks |
| 5. Site activation & IP import | Week 18 | Week 29 | 11 weeks |
| 6. First patient enrollment | Week 20 | Week 33 | Target |
How to accelerate your Venezuela clinical trial timeline
bioaccess® has identified the following strategies to compress the timeline toward the 18-week best case:
- Engage bioaccess® early — regulatory intelligence and site pre-identification save 4-6 weeks
- Ensure all CTA documents are complete and professionally translated before submission
- Begin ethics committee and INHRR submissions in parallel
- Start IP import logistics as soon as protocol is finalized — don't wait for INHRR approval
- Use bioaccess®'s pre-qualified investigator network to skip lengthy site searches
- Consider Venezuela as part of a multi-country LATAM strategy for enrollment acceleration
**Ready to start your clinical trial in Venezuela?**
bioaccess® has the regulatory expertise and operational infrastructure to launch your trial in Venezuela within optimal timelines. Contact us to get your personalized timeline assessment, or explore our full-service clinical operations.
Frequently asked questions
Get your FIH roadmap for Venezuela
From protocol to enrollment — bioaccess® compresses your Venezuela trial timeline.
Get your FIH roadmap
View case studies